Logo image of ACET

ADICET BIO INC (ACET) Stock Fundamental Analysis

NASDAQ:ACET - Nasdaq - US0070021086 - Common Stock - Currency: USD

0.9734  -0.03 (-2.66%)

After market: 0.9657 -0.01 (-0.79%)

Fundamental Rating

3

Taking everything into account, ACET scores 3 out of 10 in our fundamental rating. ACET was compared to 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ACET as it has an excellent financial health rating, but there are worries on the profitability. ACET has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACET had negative earnings in the past year.
In the past year ACET has reported a negative cash flow from operations.
In the past 5 years ACET always reported negative net income.
ACET had a negative operating cash flow in each of the past 5 years.
ACET Yearly Net Income VS EBIT VS OCF VS FCFACET Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

ACET's Return On Assets of -47.93% is in line compared to the rest of the industry. ACET outperforms 48.13% of its industry peers.
ACET has a Return On Equity of -55.73%. This is in the better half of the industry: ACET outperforms 62.17% of its industry peers.
Industry RankSector Rank
ROA -47.93%
ROE -55.73%
ROIC N/A
ROA(3y)-36.07%
ROA(5y)-46.69%
ROE(3y)-42.72%
ROE(5y)-63.13%
ROIC(3y)N/A
ROIC(5y)N/A
ACET Yearly ROA, ROE, ROICACET Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

ACET does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACET Yearly Profit, Operating, Gross MarginsACET Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

More info and screens

7

2. Health

2.1 Basic Checks

ACET does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACET has more shares outstanding
ACET has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ACET. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACET Yearly Shares OutstandingACET Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ACET Yearly Total Debt VS Total AssetsACET Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

ACET has an Altman-Z score of -2.05. This is a bad value and indicates that ACET is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.05, ACET perfoms like the industry average, outperforming 52.93% of the companies in the same industry.
ACET has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.05
ROIC/WACCN/A
WACC9.44%
ACET Yearly LT Debt VS Equity VS FCFACET Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

ACET has a Current Ratio of 10.64. This indicates that ACET is financially healthy and has no problem in meeting its short term obligations.
ACET has a better Current ratio (10.64) than 81.71% of its industry peers.
ACET has a Quick Ratio of 10.64. This indicates that ACET is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.64, ACET belongs to the top of the industry, outperforming 81.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.64
Quick Ratio 10.64
ACET Yearly Current Assets VS Current LiabilitesACET Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.96% over the past year.
Looking at the last year, ACET shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)48.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.69%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.20% on average over the next years. This is quite good.
The Revenue is expected to grow by 167.54% on average over the next years. This is a very strong growth
EPS Next Y57.58%
EPS Next 2Y25.8%
EPS Next 3Y19.03%
EPS Next 5Y14.2%
Revenue Next Year-100%
Revenue Next 2Y152.98%
Revenue Next 3Y85.66%
Revenue Next 5Y167.54%

3.3 Evolution

ACET Yearly Revenue VS EstimatesACET Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
ACET Yearly EPS VS EstimatesACET Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACET. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACET. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACET Price Earnings VS Forward Price EarningsACET Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACET Per share dataACET EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

ACET's earnings are expected to grow with 19.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.8%
EPS Next 3Y19.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACET!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADICET BIO INC

NASDAQ:ACET (2/21/2025, 8:00:00 PM)

After market: 0.9657 -0.01 (-0.79%)

0.9734

-0.03 (-2.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-12 2025-03-12/amc
Inst Owners62.48%
Inst Owner Change0.59%
Ins Owners1.58%
Ins Owner Change-3.5%
Market Cap80.21M
Analysts82.86
Price Target6.53 (570.84%)
Short Float %4.33%
Short Ratio3.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.58%
Min EPS beat(2)2.1%
Max EPS beat(2)11.06%
EPS beat(4)4
Avg EPS beat(4)6.82%
Min EPS beat(4)2.1%
Max EPS beat(4)11.52%
EPS beat(8)4
Avg EPS beat(8)-23.82%
EPS beat(12)6
Avg EPS beat(12)-5.45%
EPS beat(16)9
Avg EPS beat(16)-2.63%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.54%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.38
P/tB 0.38
EV/EBITDA N/A
EPS(TTM)-1.71
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0
BVpS2.57
TBVpS2.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.93%
ROE -55.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.07%
ROA(5y)-46.69%
ROE(3y)-42.72%
ROE(5y)-63.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.47%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.64
Quick Ratio 10.64
Altman-Z -2.05
F-Score6
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)523.67%
Cap/Depr(5y)371.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.69%
EPS Next Y57.58%
EPS Next 2Y25.8%
EPS Next 3Y19.03%
EPS Next 5Y14.2%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y152.98%
Revenue Next 3Y85.66%
Revenue Next 5Y167.54%
EBIT growth 1Y3.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.96%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-76.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-133.08%
OCF growth 3YN/A
OCF growth 5YN/A